ADAM9 as a potential target molecule in cancer

Current Pharmaceutical Design

Volumn 15, Issue 20, 2009, Pages 2282-2287

  Peduto, Lucie ^a  

^a CNRS   (France)

Author keywords

ADAM9; Ectodomain shedding; EGF; FGFR2iiib; Prostate cancer; Tumorigenesis

Indexed keywords

ADAM PROTEIN; ANGIOPOIETIN RECEPTOR; CD40 ANTIGEN; EPHRIN RECEPTOR B4; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PROTEIN ADAM10; PROTEIN ADAM9; TAMOXIFEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

BREAST CANCER; BREAST CARCINOMA; CARCINOGENESIS; CATALYSIS; CELL ADHESION; CELL MATURATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; GENE OVEREXPRESSION; GENETIC DISORDER; HUMAN; KIDNEY CANCER; LIVER CANCER; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR VASCULARIZATION;

ADAM PROTEINS; ANIMALS; CELL ADHESION; HUMANS; MEMBRANE PROTEINS; MICE; NEOPLASMS;

EID: 69249117009     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209788682415     Document Type: Review

References (60)

1. Murphy G. The ADAMs: Signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8: 929-41.
2. Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008; 90: 369-79.
3. Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y, Fujisawa-Sehara A. A metalloprotease-disintegrin participating in myoblast fusion. Nature 1995; 377: 652-6.
4. Weskamp G, Kratzschmar J, Reid MS, Blobel CP. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J Cell Biol 1996; 132: 717-26.
5. Hotoda N, Koike H, Sasagawa N, Ishiura S. A secreted form of human ADAM9 has an alpha-secretase activity for APP. Biochem Biophys Res Commun 2002; 293: 800-5.
6. Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res 2005; 65: 4728-38.
7. Cai H, Kratzschmar J, Alfandari D, Hunnicutt G, Blobel CP. Neural crest-specific and general expression of distinct metalloprotease-disintegrins in early Xenopus laevis development. Dev Biol 1998; 204: 508-24.
8. Weskamp G, Cai H, Brodie TA, Higashyama S, Manova K, Ludwig T, et al. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol Cell Biol 2002; 22: 1537-44.
9. Horiuchi K, Zhou HM, Kelly K, Manova K, Blobel CP. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol 2005; 3: 3.
10. Zhou HM, Weskamp G, Chesneau V, Sahin U, Vortkamp A, Horiuchi K, et al. Essential role for ADAM19 in cardiovascular morphogenesis. Mol Cell Biol 2004; 24: 96-104.
11. Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res 2005; 65: 9312-9.
12. Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro P, Blobel CP. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol 2009; 9: 9.
13. Roghani M, Becherer JD, Moss ML, Atherton RE, Erdjument-Bromage H, Arribas J, et al. Metalloprotease-disintegrin MDC9: Intracellular maturation and catalytic activity. J Biol Chem 1999; 274: 3531-40.
14. Izumi Y, Hirata M, Hasuwa H, Iwamoto R, Umata T, Miyado K, et al. A metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J 1998; 17: 7260-72.
15. Howard L, Nelson KK, Maciewicz RA, Blobel CP. Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1. J Biol Chem 1999; 274: 31693-9.
16. Tanaka M, Nanba D, Mori S, Shiba F, Ishiguro H, Yoshino K, et al. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J Biol Chem 2004; 279: 41950-9.
17. Mori S, Tanaka M, Nanba D, Nishiwaki E, Ishiguro H, Higashiyama S, et al. PACSIN3 binds ADAM12/meltrin alpha and up-regulates ectodomain shedding of heparin-binding epidermal growth factor-like growth factor. J Biol Chem 2003; 278: 46029-34.
18. Nelson KK, Schlondorff J, Blobel CP. Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta. Biochem J 1999; 343: 673-80.
19. Amour A, Knight CG, English WR, Webster A, Slocombe PM, Knauper V, et al. The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett 2002; 524: 154-8.
20. Blobel CP. ADAMs: Key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32-43.
21. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med 2008; 29: 258-89.
22. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 2004; 164: 769-79.
23. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, Murphy G, et al. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 2007; 18: 176-88.
24. Tousseyn TA, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of notch and other proteins, is processed itself by ADAMS 9, -15, and gamma-secretase. J Biol Chem 2009; 11: 11.
25. Cisse MA, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B, Checler F. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem 2005; 280: 40624-31.
26. Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A. Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem 2007; 282: 436-44.
27. Mohan S, Thompson GR, Amaar YG, Hathaway G, Tschesche H, Baylink DJ. ADAM-9 is an insulin-like growth factor binding protein-5 protease produced and secreted by human osteoblasts. Biochemistry 2002; 41: 15394-403.
28. Ito N, Nomura S, Iwase A, Ito T, Kikkawa F, Tsujimoto M, et al. ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem Biophys Res Commun 2004; 314: 1008-13.
29. Schwettmann L, Tschesche H. Cloning and expression in Pichia pastoris of metalloprotease domain of ADAM 9 catalytically active against fibronectin. Protein Expr Purif 2001; 21: 65-70.
30. Koike H, Tomioka S, Sorimachi H, Saido TC, Maruyama K, Okuyama A, et al. Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem J 1999; 343: 371-5.
31. Deuss M, Reiss K, Hartmann D. Part-time alpha-secretases: The functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res 2008; 5: 187-201.
32. Huang TF, Holt JC, Lukasiewicz H, Niewiarowski S. Trigramin. A low molecular weight peptide inhibiting fibrinogen interaction with platelet receptors expressed on glycoprotein IIb-IIIa complex. J Biol Chem 1987; 262: 16157-63.
33. Calvete JJ, Marcinkiewicz C, Monleon D, Esteve V, Celda B, Juarez P, et al. Snake venom disintegrins: Evolution of structure and function. Toxicon 2005; 45: 1063-74.
34. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cell-matrix interactions. J Cell Biol 1995; 131: 275-8.
35. Evans JP. Fertilin beta and other ADAMs as integrin ligands: Insights into cell adhesion and fertilization. Bioessays 2001; 23: 628-39.
36. White JM. ADAMs: Modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 2003; 15: 598-606.
37. Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G. Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta (1)integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci 2000; 113: 2319-28.
38. Zhou M, Graham R, Russell G, Croucher PI. MDC-9 (ADAM-9/Meltrin gamma) functions as an adhesion molecule by binding the alpha(v)beta(5) integrin. Biochem Biophys Res Commun 2001; 280: 574-80.
39. Karadag A, Zhou M, Croucher PI. ADAM-9 (MDC-9/meltringamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin. Blood 2006; 107: 3271-8
40. Takeda S, Igarashi T, Mori H, Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J 2006; 25: 2388-96.
41. Zigrino P, Mauch C, Fox JW, Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer 2005; 116: 853-9.
42. O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003; 105: 754-61.
43. Le Pabic H, Bonnier D, Wewer UM, Coutand A, Musso O, Baffet G, et al. ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology 2003; 37: 1056-66.
44. Tannapfel A, Anhalt K, Hausermann P, Sommerer F, Benicke M, Uhlmann D, et al. Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays. J Pathol 2003; 201: 238-49.
45. Grutzmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, et al. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004; 90: 1053-8.
46. Yamada D, Ohuchida K, Mizumoto K, Ohhashi S, Yu J, Egami T, et al. Increased expression of ADAM 9 and ADAM 15 mRNA in pancreatic cancer. Anticancer Res 2007; 27: 793-9.
47. Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005; 26: 17-24.
48. Fritzsche FR, Wassermann K, Jung M, Tolle A, Kristiansen I, Lein M, et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer 2008; 8: 179.
49. Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 2008; 54: 1097-106
50. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006; 10: 529-41.
51. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: A retrospective study. Clin Cancer Res 2005; 11: 7311-21.
52. Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res 2004; 64: 4190-6.
53. Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, et al. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res 2006; 312: 331-9.
54. Singh B, Schneider M, Knyazev P, Ullrich A. UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Int J Cancer 2009; 124: 531-9.
55. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol Cell Biochem 2003; 253: 89-101.
56. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 2006; 66: 9519-26.
57. McCulloch DR, Harvey M, Herington AC. The expression of the ADAMs proteases in prostate cancer cell lines and their regulation by dihydrotestosterone. Mol Cell Endocrinol 2000; 167: 11-21.
58. Shigemura K, Sung SY, Kubo H, Arnold RS, Fujisawa M, Gotoh A, et al. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 2007; 67: 722-31.
59. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 2004; 24: 5172-83.
60. Schuhmacher M, Kohlhuber F, Holzel M, Kaiser C, Burtscher H, Jarsch M, et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 2001; 29: 397-406.